Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Shareholders of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) will be pleased this week, given that the stock price is up 18% to US$96.23 following its latest quarterly results. The business exceeded expectations with revenue of US$60m coming in 7.2% ahead of forecasts. Statutory losses were US$0.83 a share, in line with what the analysts predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGM:RYTM Earnings and Revenue Growth May 8th 2026

Taking into account the latest results, the most recent consensus for Rhythm Pharmaceuticals from 16 analysts is for revenues of US$295.8m in 2026. If met, it would imply a major 36% increase on its revenue over the past 12 months. Losses are expected to increase slightly, to US$3.32 per share. Before this latest report, the consensus had been expecting revenues of US$287.4m and US$3.14 per share in losses. So it's pretty clear consensus is mixed on Rhythm Pharmaceuticals after the new consensus numbers; while the analysts lifted revenue numbers, they also administered a pronounced increase to per-share loss expectations.

Check out our latest analysis for Rhythm Pharmaceuticals

There was no major change to the consensus price target of US$138, with growing revenues seemingly enough to offset the concern of growing losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Rhythm Pharmaceuticals analyst has a price target of US$159 per share, while the most pessimistic values it at US$105. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Rhythm Pharmaceuticals' past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Rhythm Pharmaceuticals'historical trends, as the 51% annualised revenue growth to the end of 2026 is roughly in line with the 58% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 21% annually. So although Rhythm Pharmaceuticals is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Rhythm Pharmaceuticals analysts - going out to 2028, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments